Background & Aims: The cyclooxygenase 2 (COX-2) and ErbB/HER pathways are important
modulators of cancer cell growth. We sought to determine the effects of treatment with a …

Recent epidemiologic studies have shown a 40–50% reduction in mortality from colorectal
cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis …

NSAIDs are powerful chemopreventive agents for colon cancer, but their mechanism of
action remains unknown. Their best recognized pharmacological property is inhibition of the …

Cyclooxygenase-2 (COX-2) is upregulated in a number of epithelial cancers, including in
upper aerodigestive tract (UADT) premalignant and malignant lesions. The purpose of this …

There is now substantial evidence for a role for cyclooxygenase-2 (COX-2)-mediated
prostaglandin (PG) signalling during carcinogenesis in a number of tissues and selective …

Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs)
significantly reduce the risk and mortality from colorectal cancer, in part by inhibiting …

A large number of epidemiological studies have shown that regular use of aspirinor other
nonsteroidal anti-inflammatory drugs (NSAIDs) results in a 40–50% reduced risk of …

Cyclooxygenase (COX)-2 levels are elevated in several types of human cancer tissues.
Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both the COX-1 and …

Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing
cancer. One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the …

BACKGROUND & AIMS: Multiple studies show that continuous use of nonsteroidal anti-
inflammatory drugs (NSAIDs) lowers the risk of colon cancer in humans and carcinogen …